Rapid note: IL-6 is a survival prognostic factor in renal cell carcinoma

Immunology Letters

Volumn 58, Issue 2, 1997, Pages 121-124

  Thiounn, Nicolas ^a   Pages, Franck ^a,b   Flam, Thierry ^a   Tartour, Eric ^b   Mosseri, Véronique ^b   Zerbib, Marc ^a   Beuzeboc, Phillipe ^a   Deneux, Laurent ^b   Fridman, Wolf H ^b   Debré, Bernard ^a  

^a Hôpital Cochin ^*  (France)

^b INSTITUT CURIE   (France)

Author keywords

Immunotherapy; Interleukin 6; Renal cell carcinoma

Indexed keywords

ALPHA2 INTERFERON; FLUOROURACIL; INTERLEUKIN 2; INTERLEUKIN 6; ALPHA2A INTERFERON; ANTINEOPLASTIC ANTIMETABOLITE; BIOLOGICAL MARKER; BIOLOGICAL RESPONSE MODIFIER; BIOPTERIN; C REACTIVE PROTEIN; COLONY STIMULATING FACTOR 1; DRUG DERIVATIVE; INTERLEUKIN 2 RECEPTOR; NEOPTERIN;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CARCINOMA; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL TIME; BLOOD; IMMUNOTHERAPY; KIDNEY TUMOR; METASTASIS; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; RETROSPECTIVE STUDY; SURVIVAL;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; BIOLOGICAL MARKERS; BIOLOGICAL RESPONSE MODIFIERS; BIOPTERIN; C-REACTIVE PROTEIN; CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; FEMALE; FLUOROURACIL; HUMANS; IMMUNOTHERAPY; INTERFERON ALFA-2A; INTERLEUKIN-6; KIDNEY NEOPLASMS; MACROPHAGE COLONY-STIMULATING FACTOR; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPTERIN; PROGNOSIS; RECEPTORS, INTERLEUKIN-2; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 0031183798     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-2478(97)00036-9     Document Type: Article

References (12)

1. G. Tosato, S. Pike, J. Immunol. 141 (1988) 1556.
2. Y. Takai, G. Wong, S.C. Clark, S.J. Burakoff, S.H. Herrmann, J. Immunol. 140 (1988) 508.
3. R. Kuhweide, J. Van Damme, J.L. Ceuppens, Eur. J. Immunol. 20 (1990) 1019.
4. F. Houssiau, P.G. Coulie, D. Olive, J. Van Snick, Eur. J. Immunol. 18 (1988) 635.
5. T.A. Luger, J. Krutmann, R. Kirnbauer, A. Urbanski, T. Schwartz, G. Klappacher, A. Kock, M. Micksche, J. Malejczyk, E. Schauer, L.T. May, P.B. Sehgal, J. Immunol. 143 (1989) 1206.
6. S. Miki, M. Iwano, Y. Miki, M. Yamamoto, B. Tang, K. Yokokawa, T. Sonoda, T. Hirano, T. Kishimoto, FEBS Lett. 250 (1989) 607.
7. J. Takenawa, Y. Kanako, M. Fukyumoto, A. Fukatsu, T. Hirano, H. Fukuyama, H. Nakayama, J. Fujita, O. Yoshida, J. Natl. Cancer Inst. 83 (1991) 1668.
8. H. Serve, G. Steinhauser, B. Oberberg, W.A. Flegel, H. Northoff, W.E. Berdell, Cancer Res. 51 (1991) 3862.
9. C. Lu, M.F. Vickers, R.S. Kerbel, Proc. Natl. Acad. Sci. USA 89 (1992) 9215.
10. E. Tartour, J.Y. Blay, T. Dorval, B. Escudier, V. Mosseri, J.Y. Douillard, L. Deneux, I. Gorin, S. Negrier, C. Mathiot, P. Pouillart, W.H. Fridman, J. Clin. Oncol. 14 (1996) 1697.
11. E. Tartour, T. Dorval, V. Mosseri, L. Deneux, C. Mathiot, H. Brailly, F. Montero, I. Joyeux, P. Pouillart, W.H. Fridman, Br. J. Cancer 69 (1994) 911.
12. J.Y. Blay, S. Negrier, V. Combaret, S. Attali, E. Goillot, Y. Merrouche, A. Mercatello, A. Ravault, J.M. Tourani, J.F. Moskovtchenko, T. Philip, M. Favrot, Cancer Res. 52 (1992) 3317.